Long-Term Benefit of Dabrafenib Plus Trametinib in Melanoma Confirmed in 5-Year Follow-Up of COMBI-AD Study

Source: Targeted Oncology, May 2020

The long-term benefit of adjuvant dabrafenib (Tafinlar) plus trametinib (Mekinist) as treatment of patients with resected, stage III BRAF V600E/K-mutant melanoma were validated by 5-year data from the phase 3 COMBI-AD study, according to a presentation from the 2020 American Soceity of Clinical Oncology (ASCO) Virtual Scientific Program.

The 4- and 5-year relapse-free survival (RFS) rates were 55% (95% CI, 50-60) and 52% (95% CI, 48-58) with the doublet therapy versus 38% (95% CI, 34-43) and 36% (95% CI, 32-41) with placebo.

“There is a longer than 50% relapse-free survival,” said lead study author Axel Hauschild, MD, during a presentation at the 2020 ASCO Virtual Scientific Program. “The relapse-free survival curves for both treatment arms appear to be reaching a plateau, which is a good sign if we are talking about cure.”